Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement
| Condition | Degenerative Arthritis, Rheumatoid Arthritis, Traumatic Arthritis |
|---|---|
| Phase | N/A |
| Sponsor | Smith & Nephew, Inc. |
| Status | Terminated |
| Enrollment | 65 participants |
| Interventions | Implantation of Integra Cadence Total Ankle System |
| Start date | Sep 18, 2017 |
| Completion date | Sep 6, 2023 |
| Results posted | Jun 22, 2026 |
Summary
This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), and systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis)
Implant Survivorship at 2 Years
| Integra® Cadence™ Total Ankle System | 100 percentage of participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company